Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is 2.04 as of 2026-10-06T16:52:06.843Z.
Calculation as of: 2026-10-06T16:52:06.843Z.
Quote observation: 2026-10-06T16:50:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6dd2a4984e4340952b62e9ecd156f35eed99e3c78779d37ae6f95d3f5c845125
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
2.04
SECTOR MEDIAN · HEALTHCARE
2.38
median of 689 covered companies
CURRENT VS SECTOR MEDIAN
-14.29%
vs the sector median at left
Market Cap
$1.34B
PB Ratio
2.96
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kardigan, Inc. (KARD) | $1.26B | 2.04 | N/A | N/A | N/A |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | 3.25 | 2.79 | 2.45 | 1.92 |
| Omada Health (OMDA)vs › | $1.23B | 4.86 | 4.46 | 4.46 | 4.46 |
| Cronos Group Inc. (CRON)vs › | $1.22B | 1.14 | 0.98 | 0.81 | 0.78 |
| MannKind Corporation (MNKD)vs › | $1.22B | N/A | 194.84 | 194.84 | 194.84 |
| Innovage Holding Corp. (INNV)vs › | $1.21B | 5.15 | 4.54 | 3.10 | 2.89 |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | 30.06 | 12.45 | 6.00 | 4.99 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.34B | 2.96 | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | 3.02 | 3.43 | 1.29 | 1.04 |
| Omeros Corporation (OMER)vs › | $1.35B | N/A | 6.40 | 8.08 | 6.86 |
P/B Ratio
2.04
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
